tailieunhanh - báo cáo khoa học: "Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/ refractory non-transplant multiple myeloma patients: a single center experience from Thailand"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/ refractory non-transplant multiple myeloma patients: a single center experience from Thailand | Niparuck et al. Journal of Hematology Oncology 2010 3 1 http content 3 1 1 JOURNAL OF HEMATOLOGY ONCOLOGY LETTER TO THE EDITOR Open Access Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed refractory non-transplant multiple myeloma patients a single center experience from Thailand Pimjai Niparuck Ladda Sorakhunpipitkul Vichai Atichartakarn Suporn Chuncharunee Artit Ungkanont Pantep Aungchaisuksiri Teeraya Puavilai Saengsuree Jootar Abstract Background Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma MM patients however there were a small number of studies written about the results of thalidomide therapy in nontransplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy. Results Induction regimens with thalidomide and dexamethasone and the oral combination of melphalan prednisolone and thalidomide were administrated in 22 and 16 patients respectively. The remaining 4 patients received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen. Twenty-three out of 26 patients achieving complete remission CR and very good partial remission VGPR received thalidomide maintenance. Of the 41 evaluable patients median time of treatment was 21 months 3- 45 months ORR was with a CR VGPR. With a median follow up of 23 months 3-year- PFS and 3-year-OS were and respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in non-transplant patients receiving thalidomide maintenance therapy were 67 and 80 respectively. Conclusions Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non-transplant multiple myeloma patients. To the editor Thalidomide based therapy for multiple .